Henning Steinhagen, PhD, MBA

Henning Steinhagen, PhD, MBA has extensive experience in the life science and healthcare industry. Henning began their career in 1999 as a Research Scientist in Medicinal Chemistry at Bayer Pharmaceuticals. In 2002, they moved to Sanofi-Aventis, where they served as a Director of Medicinal Chemistry and Senior Scientist and Project Leader. From 2009 to 2016, they were Senior Vice President and Head of Global Drug Discovery at Grünenthal Pharma, and then Executive Vice President and Head of Global Drug Discovery and Site Head Verona at Aptuit. In 2014, they began working as an Independent Consultant and Senior Advisor and non-executive board member. In 2019, they became a Venture Partner at Epidarex Capital, as well as CEO and Co-founder of Epidarex Exeed Ltd. In 2020, they joined the Board of Directors of Libra Therapeutics, and in 2021 they joined the Board of Directors and Co-lead investor of Theolytics.

Henning Steinhagen, PhD, MBA has an extensive education history. Henning completed their BSc in Chemistry at The University of Freiburg from 1989 to 1991. Henning then completed an international exchange year at Dublin City University in Chemistry from 1992 to 1993. Henning then completed their Master and PhD in Chemistry (Minor Molecular Genetics) at Heidelberg University from 1991 to 1998. Henning then completed a PostDoc at Harvard University in the EJ Corey Group from 1998 to 1999. Henning then completed an Executive MBA (EMBA) at IMD in June 2018.